Ratings National Health Investors, Inc.

Equities

NHI

US63633D1046

Market Closed - Nyse 01:30:02 03/05/2024 am IST 5-day change 1st Jan Change
64.44 USD +1.64% Intraday chart for National Health Investors, Inc. +2.53% +15.38%

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • One of the major weak points of the company is its financial situation.
  • The firm trades with high earnings multiples: 22.32 times its 2024 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialized REITs

1st Jan change Capi. Investor Rating ESG Refinitiv
+15.38% 2.75B
C-
+6.55% 55.76B
A-
-7.26% 17.64B
A-
-3.18% 13.29B
A
+1.99% 7.58B
B
-17.41% 5.54B
B-
+13.09% 3.37B
C-
-0.35% 3.22B
C+
-2.36% 3.05B
B+
-1.43% 2.8B
C
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NHI Stock
  4. Ratings National Health Investors, Inc.